Alvotech-Lotus $150m biosimilar deal targets nearly $12 billion of Imfinzi and Hemlibra sales
Alvotech can receive up to about $150 million while retaining the right to sell AVT34 and AVT87 itself in the United States, a first for its US biosimilar strategy.